OHTUVAYREHCP.COM: Keyword Density Checker

Total words: 3219 | 2-word phrases: 835 | 3-word phrases: 945 | 4-word phrases: 987

PAGE INFO

Title	Try to keep the title under 60 characters (62 characters) OHTUVAYRE (ensifentrine) \| Nonsteroidal Nebulized COPD Therapy
Description	Try to keep the meta description between 50 - 160 characters (283 characters) Discover OHTUVAYRE (ensifentrine) inhalation suspension, for oral inhalation – novel first-in-class selective dual inhibitor of phosphodiesterase (PDE) 3 and PDE4, offering a nonsteroidal approach to bronchodilation and anti-inflammation for persistently symptomatic COPD patients.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	in patients with	5	0.53%
2	request a rep	5	0.53%
3	3 and 4	4	0.42%
4	chronic obstructive pulmonary	4	0.42%
5	obstructive pulmonary disease	4	0.42%
6	phosphodiesterase 3 and	3	0.32%
7	verona pathway plus	3	0.32%
8	and 4 inhibitor	3	0.32%
9	important safety information	3	0.32%
10	treatment of chronic	3	0.32%
11	of chronic obstructive	3	0.32%
12	treatment with ohtuvayre	3	0.32%
13	acute episodes of	3	0.32%
14	should be treated	3	0.32%
15	patient profiles a	3	0.32%
16	indication ohtuvayre is	3	0.32%
17	as rescue therapy	2	0.21%
18	information indication ohtuvayre	2	0.21%
19	symptoms ie as	2	0.21%
20	ie as rescue	2	0.21%
21	relief of acute	2	0.21%
22	ohtuvayre is indicated	2	0.21%
23	this site is	2	0.21%
24	the treatment of	2	0.21%
25	rescue therapy for	2	0.21%
26	therapy for the	2	0.21%
27	for the treatment	2	0.21%
28	used for the	2	0.21%
29	and important safety	2	0.21%
30	bronchospasm acute symptoms	2	0.21%

#	Keyword	Frequency	Density
1	chronic obstructive pulmonary disease	4	0.41%
2	of chronic obstructive pulmonary	3	0.30%
3	treatment of chronic obstructive	3	0.30%
4	3 and 4 inhibitor	3	0.30%
5	phosphodiesterase 3 and 4	3	0.30%
6	this site is intended	2	0.20%
7	therapy for the treatment	2	0.20%
8	important safety information contraindication	2	0.20%
9	greater than placebo in	2	0.20%
10	should be treated with	2	0.20%
11	symptoms should be treated	2	0.20%
12	acute symptoms should be	2	0.20%
13	bronchospasm acute symptoms should	2	0.20%
14	contraindicated in patients with	2	0.20%
15	site is intended for	2	0.20%
16	for the treatment of	2	0.20%
17	rescue therapy for the	2	0.20%
18	and greater than placebo	2	0.20%
19	ohtuvayre should not be	2	0.20%
20	of this product warnings	2	0.20%
21	component of this product	2	0.20%
22	any component of this	2	0.20%
23	acute episodes of bronchospasm	2	0.20%
24	of bronchospasm ohtuvayre should	2	0.20%
25	bronchospasm ohtuvayre should not	2	0.20%
26	should not be used	2	0.20%
27	as rescue therapy for	2	0.20%
28	not be used for	2	0.20%
29	be used for the	2	0.20%
30	patients with hypersensitivity to	2	0.20%
31	in patients with hypersensitivity	2	0.20%
32	symptoms ie as rescue	2	0.20%
33	ie as rescue therapy	2	0.20%
34	this product warnings and	2	0.20%
35	patients important safety information	2	0.20%
36	product warnings and precautions	2	0.20%
37	is intended for us	2	0.20%
38	intended for us healthcare	2	0.20%
39	information indication ohtuvayre is	2	0.20%
40	indication ohtuvayre is indicated	2	0.20%

#	URL	Whois	Check
1	https://ohtuvayre.com/	Whois	ohtuvayre.com
2	https://www.fda.gov/medwatch	Whois	fda.gov
3	https://www.veronapharma.com/contact-us/	Whois	veronapharma.com